Wall Street brokerages forecast that Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) will announce ($1.30) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Relmada Therapeutics’ earnings. The highest EPS estimate is ($1.27) and the lowest is ($1.32). Relmada Therapeutics posted earnings per share of ($1.56) during the same quarter last year, which suggests a positive year over year growth rate of 16.7%. The company is expected to issue its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Relmada Therapeutics will report full-year earnings of ($5.42) per share for the current financial year, with EPS estimates ranging from ($5.55) to ($5.32). For the next year, analysts anticipate that the business will post earnings of ($3.82) per share, with EPS estimates ranging from ($5.54) to ($2.70). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Relmada Therapeutics.
Relmada Therapeutics (NASDAQ:RLMD – Get Rating) last posted its earnings results on Wednesday, March 23rd. The company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.20). During the same quarter in the prior year, the company posted ($1.28) earnings per share.
Shares of NASDAQ RLMD traded down $0.24 during midday trading on Tuesday, reaching $19.35. 14,379 shares of the company traded hands, compared to its average volume of 283,669. Relmada Therapeutics has a 52 week low of $16.23 and a 52 week high of $39.66. The stock has a 50-day moving average price of $24.29 and a 200 day moving average price of $21.55. The company has a market cap of $580.33 million, a price-to-earnings ratio of -2.68 and a beta of 0.51.
In other Relmada Therapeutics news, Director Paul Edward Kelly sold 10,000 shares of the business’s stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $30.04, for a total value of $300,400.00. Following the sale, the director now directly owns 187,295 shares in the company, valued at $5,626,341.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.50% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Deutsche Bank AG increased its stake in Relmada Therapeutics by 5.2% in the 3rd quarter. Deutsche Bank AG now owns 16,481 shares of the company’s stock worth $432,000 after purchasing an additional 820 shares in the last quarter. SG Americas Securities LLC increased its stake in Relmada Therapeutics by 2,172.3% in the 4th quarter. SG Americas Securities LLC now owns 154,450 shares of the company’s stock worth $3,480,000 after purchasing an additional 147,653 shares in the last quarter. Lindbrook Capital LLC purchased a new position in Relmada Therapeutics in the 4th quarter worth about $56,000. Geode Capital Management LLC increased its stake in Relmada Therapeutics by 3.8% in the 3rd quarter. Geode Capital Management LLC now owns 253,703 shares of the company’s stock worth $6,649,000 after purchasing an additional 9,371 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Relmada Therapeutics by 310.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 53,204 shares of the company’s stock worth $1,394,000 after purchasing an additional 40,239 shares in the last quarter. 76.11% of the stock is currently owned by hedge funds and other institutional investors.
Relmada Therapeutics Company Profile (Get Rating)
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.
- Get a free copy of the StockNews.com research report on Relmada Therapeutics (RLMD)
- Zoom Video Communications Is Primed To Launch Higher
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Institutions Buy The Dip In Petco Health and Wellness Company
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.